טאקזירו
takeda israel ltd - lanadelumab - תמיסה להזרקה - lanadelumab 150 mg/ml - lanadelumab
אורלאדיאו 110 מג
neopharm (israel)1996 ltd - berotralstat as dihydrochloride - קפסולות - berotralstat as dihydrochloride 110 mg - berotralstat
אורלאדיאו 150 מג
neopharm (israel) 1996 ltd - berotralstat as dihydrochloride - קפסולות - berotralstat as dihydrochloride 150 mg - berotralstat
אילאריס 150 מגמל
novartis israel ltd - canakinumab - אבקה להכנת תמיסה לזריקה - canakinumab 150 mg / 1 ml - canakinumab - canakinumab - cryopyrin - associated periodic syndromes (caps) in adults, adolescents and children aged 2 years and older with body weight above 7.5 kg, including : - mucle - wells syndrome (mws), - neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca), - severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.gouty arthritis:ilaris is indicated for the symptomatic treatment of adults patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
אילאריס 150 מגמל תמיסה להזרקה
novartis israel ltd - canakinumab - תמיסה להזרקה - canakinumab 150 mg / 1 ml - canakinumab
קינרט 100 מג תמיסה להזרקה
megapharm ltd - anakinra - תמיסה להזרקה - anakinra 150 mg/ml - anakinra - anakinra - kineret is indicated for the treatment of the signs and symptoms of rheumatoid arthritis in combination with methotrexate, in patients with an inadequate response to methotrexate alone.